READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/medigus/

The company's lead product is the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system, a comprehensive endoscopic device that incorporates the latest technological advancements to deliver a more patient-friendly option for Transoral Fundoplication (TF), the procedure is intended to treat the leading cause of GERD (gastroesophageal reflux disease) -- a dysfunctional valve between the esophagus and stomach.

Read more about the MDGS products and the most recent financial data READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/medigus/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 505016

"/> Medigus Restructuring Could Prove to be a Smart Move « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
Great News! MarketersMedia is officially entering into a long-term partnership with Vertical News Network.
Learn More
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / Medigus Restructuring Could Prove to be a Smart Move

Medigus Restructuring Could Prove to be a Smart Move

Share This Press Release

NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Medigus Ltd. (NASDAQ: MDGS), a medical device company that develops, manufactures, and markets surgical endostaplers and direct vision systems for minimally invasive medical procedures or other commercial uses.

On Wednesday, July 11, 2018, MDGS shares were at $2.10 (+69.35) during intra-day trading. Share volume was over 10 million compared to a daily average of 132 thousand.

On July 9, 2018, the company filed form 6-K with the following information: The Company will effect a reverse split of the Company's ordinary shares at the ratio of 10:1, such that each ten ordinary shares, par value NIS 0.10 per share, shall be consolidated into one ordinary share, par value NIS 1.00 (the Reverse Split). See more in our full report.

More about the reverse split and a full analysis available here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/medigus/

The company's lead product is the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system, a comprehensive endoscopic device that incorporates the latest technological advancements to deliver a more patient-friendly option for Transoral Fundoplication (TF), the procedure is intended to treat the leading cause of GERD (gastroesophageal reflux disease) -- a dysfunctional valve between the esophagus and stomach.

Read more about the MDGS products and the most recent financial data READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/medigus/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 505016

NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Medigus Ltd. (NASDAQ: MDGS), a medical device company that develops, manufactures, and markets surgical endostaplers and direct vision systems for minimally invasive medical procedures or other commercial uses.

On Wednesday, July 11, 2018, MDGS shares were at $2.10 (+69.35) during intra-day trading. Share volume was over 10 million compared to a daily average of 132 thousand.

On July 9, 2018, the company filed form 6-K with the following information: The Company will effect a reverse split of the Company's ordinary shares at the ratio of 10:1, such that each ten ordinary shares, par value NIS 0.10 per share, shall be consolidated into one ordinary share, par value NIS 1.00 (the Reverse Split). See more in our full report.

More about the reverse split and a full analysis available here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/medigus/

The company's lead product is the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system, a comprehensive endoscopic device that incorporates the latest technological advancements to deliver a more patient-friendly option for Transoral Fundoplication (TF), the procedure is intended to treat the leading cause of GERD (gastroesophageal reflux disease) -- a dysfunctional valve between the esophagus and stomach.

Read more about the MDGS products and the most recent financial data READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/medigus/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 505016

Source URL: https://marketersmedia.com/medigus-restructuring-could-prove-to-be-a-smart-move/376682

Source: AccessWire

Release ID: 376682

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2018 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).